VEDOLIZUMAB RATES OF MUCOSAL HEALING IN CROHN'S DISEASE: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS OF REAL-WORLD

被引：0
|
作者：
Danese, Silvio
Kamble, Pravin
Yang, Jin
Le Moine, Jean-Gabriel
Khan, Shahnaz
Hawe, Emma
Agboton, Christian
Wang, Song
Irving, Peter M.
机构：
来源：
GASTROENTEROLOGY | 2021年 / 160卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su463
引用
收藏
页码：S702 / S703
页数：2
相关论文
共 50 条
  • [31] Real-world subcutaneous infliximab for inflammatory bowel disease: A systematic review and meta-analysis
    Chetwood, J.
    Tran, Y.
    Subramanian, S.
    Smith, P.
    Iborra Colomino, M.
    Buisson, A.
    Paramsothy, S.
    Leong, R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 160 - 161
  • [32] Treatment of Mammary Paget Disease: A systematic review and meta-analysis of real-world data
    Lin, Cheng-Wei
    Chiang, Meng-Hsuan
    Tam, Ka-Wai
    INTERNATIONAL JOURNAL OF SURGERY, 2022, 107
  • [33] Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis
    Attauabi, M.
    Madsen, G. R.
    Bendtsen, F.
    Seidelin, J. B.
    Burisch, J.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I483 - I484
  • [34] Healing of Perineal Wounds after Proctectomy for Crohn's Disease: A Systematic Review and Meta-Analysis
    Alipouriani, A.
    Erozkan, K.
    Schabl, L.
    Holubar, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I631 - I631
  • [35] Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis
    Attauabi, M.
    Madsen, G. R.
    Bendtsen, F.
    Seidelin, J. B.
    Burisch, J.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I483 - I484
  • [36] Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis
    Attauabi, Mohamed
    Madsen, Gorm Roager
    Bendtsen, Flemming
    Seidelin, Jakob Benedict
    Burisch, Johan
    DIGESTIVE AND LIVER DISEASE, 2022, 54 (09) : 1168 - 1178
  • [37] Real-World Effectiveness of Vedolizumab Dose Escalation in Patients With Inflammatory Bowel Disease: A Systematic Literature Review
    Patel, Dipen
    Martin, Stephan
    Luo, Michelle
    Ursos, Lyann
    Lirio, Richard A.
    Kamble, Pravin
    Wang, Song
    CROHNS & COLITIS 360, 2022, 4 (03)
  • [38] Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease
    Jairath, V.
    Zou, G.
    Parker, C. E.
    MacDonald, J. K.
    Mosli, M. H.
    AlAmeel, T.
    Al Beshir, M.
    AlMadi, M.
    Al-Taweel, T.
    Atkinson, N. S. S.
    Biswas, S.
    Chapman, T. P.
    Dulai, P. S.
    Glaire, M. A.
    Hoekman, D.
    Kherad, O.
    Koutsoumpas, A.
    Minas, E.
    Restellini, S.
    Samaan, M. A.
    Khanna, R.
    Levesque, B. G.
    D'Haens, G.
    Sandborn, W. J.
    Feagan, B. G.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (08) : 1021 - 1042
  • [39] Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence
    Engel, Tal
    Yung, Diana E.
    Ma, Christopher
    Pariente, Benjamin
    Wils, Pauline
    Eliakim, Rami
    Ungar, Bella
    Ben-Horin, Shomron
    Kopylov, Uri
    DIGESTIVE AND LIVER DISEASE, 2019, 51 (09) : 1232 - 1240
  • [40] Real-world persistence of ustekinumab vs infliximab and adalimumab in patients with Crohn's disease: A meta-analysis
    Yiu, T. H.
    Ko, Y.
    Pudipeddi, A.
    Chetwood, J.
    Leong, R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 195 - 195
12345